Mylan Executive Chairman Robert Coury is telling Teva Pharmaceutical Industries to “stop playing games with our company” in a strongly worded letter released Monday.
Teva said back in April it wanted to make a $40 billion bid to acquire the generic pharmaceutical company that is run out of Washington County. The bid was rejected by Mylan’s board — and Coury in a strongly worded responses — but Teva has kept interest even as Mylan pursues its own unsolicited bid for another generic pharmaceutical company, Perrigo plc.
Coury wrote that without “an actual offer” or the timing, Teva should provide “unequivocal clarification” about what it wants to do with Mylan. The letter was sent to Teva’s CEO and also filed with the SEC.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
South Africa Approves Canal+ MultiChoice Deal
May 21, 2025 by
CPI
WhatsApp Co-Founder Undermines Antitrust Allegations Against Meta in Court Testimony
May 21, 2025 by
CPI
OpenAI Acquires Jony Ive’s io for $6.4B to Pioneer Post-Smartphone Devices
May 21, 2025 by
CPI
Dior Commits €2 Million to Labor Initiatives in Italian Antitrust Settlement
May 21, 2025 by
CPI
Indonesia’s Antitrust Watchdog Probes Potential Risks of Grab-GoTo Merger
May 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros